{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020543","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.899662+00:00","generated_at":"2026-06-01T13:44:24.699554+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CFO Jeffrey Church retiring June 1; David Gaiero appointed as successor","bullets":["Jeffrey Church to retire as CFO effective June 1, 2024; will serve as consultant through Dec 31, 2024.","Church receives retirement bonus of $428,615; monthly consulting retainer of $10,000 plus $250/hr over 40 hrs.","David Gaiero appointed CFO via Monomoy Advisors; monthly fee of $35,000 starting June 1, 2024.","Gaiero is a partner at Monomoy, served as CFO of Cyteir Therapeutics and interim CFO at Wave Life Sciences.","Church's vested stock options extended to original expiration; unvested options treated per plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020543","json":"https://secwatch.observer/filing/0001493152-24-020543.json","markdown":"https://secwatch.observer/filing/0001493152-24-020543.md","text":"https://secwatch.observer/filing/0001493152-24-020543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T13:44:24.699554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a5d201d35","claim":"Jeffrey Church retired as Chief Financial Officer at Imunon, Inc..","evidence_excerpt":"On May 15, 2024, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from all positions with the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"7573818ba8","claim":"David Gaiero was appointed as Chief Financial Officer at Imunon, Inc..","evidence_excerpt":"effective June 1, 2024, the Company appointed David Gaiero to serve as the Company’s new Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315224020543/0001493152-24-020543-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}